=> d l1
L1 HAS NO ANSWERS
L1 STR



VAR G1=10/11/12/14/15
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 16 13 6
NUMBER OF NODES IS 28

STEREO ATTRIBUTES: NONE

=> d his l3

(FILE 'REGISTRY' ENTERED AT 16:23:41 ON 22 JUL 2008)
L3 0 S L1 FUL

=> d l6
L6 HAS NO ANSWERS
L6 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 6 13 16
NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

=> d his l8

(FILE 'REGISTRY' ENTERED AT 16:23:41 ON 22 JUL 2008)
L8 163 S L6 FUL

=> d l13
L13 HAS NO ANSWERS
L13 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 13 16 7
NUMBER OF NODES IS 26

STEREO ATTRIBUTES: NONE

=> d his l14

(FILE 'REGISTRY' ENTERED AT 16:23:41 ON 22 JUL 2008)
L14 2 SEARCH L13 SSS SUB=L8 FUL

=> fil caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	489.92	490.34

FILE 'CAPLUS' ENTERED AT 16:33:49 ON 22 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Jul 2008 VOL 149 ISS 4
FILE LAST UPDATED: 21 Jul 2008 (20080721/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

```
=> s l14
L15          2 L14

=> d bib abs hitstr 1-2

L15  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
AN   1999:246879  CAPLUS
DN   130:296684
TI   Preparation of indazole- and 2-oxobenzamidazole-3-carboxamides as 5-HT4
     agonists and antagonists
IN   Cohen, Marlene Lois; Schaus, John Mehnert; Thompson, Dennis Charles
PA   Eli Lilly and Company, USA
SO   Eur. Pat. Appl., 26 pp.
     CODEN: EPXXDW
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     ---------------     ----   --------    --------------------    --------
PI   EP 908459            A1    19990414    EP 1998-308069          19981005
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
             SI, LT, LV, FI, RO
     US 6069152           A     20000530    US 1997-946495          19971007
     CA 2304826           A1    19990415    CA 1998-2304826         19980924
     WO 9917772           A1    19990415    WO 1998-US19992         19980924
         W:  AL, AM, AT, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE,
             GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG,
             SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA,
             GN, GW, ML, MR, NE, SN, TD, TG
     JP 2001518504        T     20011016    JP 2000-514643          19980924
     US 6117882           A     20000912    US 1999-338707          19990623
PRAI US 1997-946495       A     19971007
     WO 1998-US19992      W     19980924
OS   MARPAT 130:296684
GI
```



I



II

AB The title compds. [I; AD = C:N,NC:O; n = 1-5; R = H, halo, alkyl, etc.; R1 = H, alkyl, (un)substituted cycloalkyl; R2, R3 = H; R2R3 taken together form a bridge of 1-4 methylene units; X = OR4, NR4R5; R4 = H, alkyl, (un)substituted cycloalkyl, etc.; R5 = H; NR4R5 = pyrrolidino, piperazino, piperidino, etc.], antagonists and partial agonists for the serotonin receptor 5-HT4 which are useful for treatment of disorders caused by or affected by dysfunction of the 5-HT4 receptor such as anxiety, pain, depression, schizophrenia, memory disorders, dementia, irritable bowel syndrome, nausea, gastroesophageal reflux disease, dyspepsia, gastrointestinal motility disorders, constipation, atrial fibrillation, arrhythmias, tachycardia, urinary retention, urinary incontinence, or pain on urination, were prepared and formulated. E.g., methanesulfonylation of N-[1-(2-aminoethyl)piperidin-4-yl]-1-isopropylindazole-3-carboxamide (preparation given) afforded 60% II. Compds. I reduced the observed relaxations of esophagus smooth muscle (of rats) at ≤ 10 μM.

IT 207296-80-8P 207296-81-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indazole- and 2-oxobenzamidazole-3-carboxamides as 5-HT4 agonists and antagonists)

RN 207296-80-8 CAPLUS

CN 1H-Indazole-3-carboxamide, N-[1-[2-(benzoylamino)ethyl]-4-piperidinyl]-1-(1-methylethyl)- (CA INDEX NAME)



RN 207296-81-9 CAPLUS
CN 1H-Indazole-3-carboxamide, N-[1-[2-(benzoylamino)ethyl]-4-piperidinyl]-1-(1-methylethyl)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 207296-80-8
CMF C25 H31 N5 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 1998:270001 CAPLUS
DN 128:316920
OREF 128:62633a
TI Synthesis and Structure-Activity Relationships of Potent and Orally Active 5-HT4 Receptor Antagonists: Indazole and Benzimidazolone Derivatives
AU Schaus, John M.; Thompson, Dennis C.; Bloomquist, William E.; Susemichel, Alice D.; Calligaro, David O.; Cohen, Marlene L.
CS Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA
SO Journal of Medicinal Chemistry (1998), 41(11), 1943-1955
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
AB Indole-3-carboxamides, indazole-3-carboxamides, and benzimidazolone-3-carboxamides were synthesized and evaluated for antagonist affinity at the 5-HT4 receptor in the rat esophagus. The endo-3-tropanamine derivs. in the indazole and benzimidazolone series possessed greater 5-HT4 receptor affinity than the corresponding indole analogs. 5-HT4 receptor antagonist affinity was further increased by alkylation at N-1 of the aromatic heterocycle. In 1-isopropylindazole-3-carboxamides, replacement of the bicyclic tropane ring system with the monocyclic piperidine ring system or an acyclic aminoalkylene chain led to potent 5-HT4 receptor antagonists. In particular, those systems in which the basic amine was substituted with groups capable of forming H bonds showed increased 5-HT4 receptor antagonist activity. While some of these compds. displayed high affinity

for other neurotransmitter receptors (in particular, 5-HT3, α1, and 5-HT2A receptors), as the conformational flexibility of the amine moiety increased, the selectivity for the 5-HT4 receptor also increased. From this series of compds., the authors identified LY353433 (1-(1-methylethyl)-N-[2-[4-[(tricyclo[3.3.1.13,7]dec-1-ylcarbonyl)amino]-1-piperidinyl]ethyl]-1H-indazole-3-carboxamide) as a potent and selective 5-HT4 receptor antagonist with clin. suitable pharmacodynamics.

IT 207296-81-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(synthesis and structure-activity relationships of potent and orally active indazole and benzimidazolone 5-HT4 receptor antagonists)

RN 207296-81-9 CAPLUS

CN 1H-Indazole-3-carboxamide, N-[1-[2-(benzoylamino)ethyl]-4-piperidinyl]-1-(1-methylethyl)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 207296-80-8
CMF C25 H31 N5 O2



CM 2

CRN 144-62-7
CMF C2 H2 O4



RE.CNT 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT